The two Cs: Ceramide and cardiomyopathy

Journal of Lipid Research

Volumn 49, Issue 10, 2008, Pages 2077-2078

  Getz, Godfrey S ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CERAMIDE; FATTY ACID; GLUCOSE; GLYCOSYLPHOSPHATIDYLINOSITOL; LIPOPROTEIN LIPASE; MYOSIN HEAVY CHAIN; SERINE PALMITOYLTRANSFERASE; THERMOZYMOCIDIN;

CARDIOMYOPATHY; CARDIOTOXICITY; CONGESTIVE CARDIOMYOPATHY; DRUG TOLERABILITY; ENZYME ACTIVITY; FATTY ACID METABOLISM; GLUCOSE METABOLISM; HEART FUNCTION; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; LIPID METABOLISM; LIPID OXIDATION; LIPID STORAGE; LIPID TRANSPORT; LONG TERM CARE; NONHUMAN; NOTE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; TRANSGENE;

ANIMALS; CARDIOMYOPATHIES; CARDIOMYOPATHY, DILATED; CERAMIDES; MICE; MYOCARDIUM;

EID: 67649770889     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.E800015-JLR200     Document Type: Note

References (11)

1. Park, T-S., Y. Hu, H-L. Noh, K. Drosatos, K. Okajima, J. Buchanan, J. Tuinei, S. Homma, X-C. Jiang, E. D. Abel, et al. 2008 Ceramide is a cardiotoxin in lipotoxic cardiomyopathy. J. Lipid Res. 49: 2101-2112.
2. Yagyu, H., G. Chen, M. Yokoyama, K. Hirata, A. Augustus, Y. Kako, T. Seo, Y. Hu, E. P. Lutz, M. Merkel, et al. 2003. Lipoprotein lipase (LpL) on the surface of cardiomyocytes increases lipid uptake and produces a cardiomyopathy. J. Clin. Invest. 111: 419-426.
3. Holland, W. L., and S. A. Summers. 2008. Sphingolipids, insulin resistance, and metabolic disease. New Insights from in Vivo Manipulation of Sphingolipid Metabolism Endocrine Reviews. 29: 381-402.
4. Olivecrona, T., and G. Bengtsson-Olivecrona. 1987. Lipoprotein lipase from milk-the model enzyme in lipoprotein lipase research, In Lipoprotein Lipase. J. Borensztajn, editor. Evener, Chicago. 15-58.
5. Laviad, E. L., L. Albee, I. Pankova-Kholmyansky, S. Epstein, H. Park, A. H. Merrill, Jr., and A. H. Futerman. 2008. Characterization of Ceramide Synthase 2 Tissue distribution, substrate specificity, and inhibition by sphingosine 1-phosphate. J. Biol. Chem. 283: 5677-5684.
6. Listenberger, L. L., and J. E. Schaffer. 2002. Mechanisms of lipoapoptosis: implications for human heart disease. Trends Cardiovasc. Med. 12: 134-138.
7. Stratford, S., K. L. Hoehn, F. Liu, and S. A. Summers. 2004. Regulation of insulin action by ceramide: dual mechanisms linking ceramide accumulation to the inhibition of Akt/protein kinase B. J. Biol. Chem. 279: 36608-36615.
8. Finck, B. N., X. Han, M. Courtois, F. Aimond, J. M. Nerbonne, A. Kovacs, R. W. Gross, and D. P. Kelly. 2003. A critical role for PPARα-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation by dietary fat content. Proc. Natl Acad. Sci. 100: 1226-1231.
9. Son, N. H., T. S. Park, H. Yamashita, M. Yokoyama, L. A. Huggins, K. Okajima, S. Homma, M. J. Szabolcs, L. S. Huang, and I. J. Goldberg. 2007. Cardiomyocyte expression of PPARg leads to cardiac dysfunction in mice. J. Clin. Invest. 117: 2791-2801.
10. Chiu, H. C., A. Kovacs, D. A. Ford, F. F. Hsu, R. Garcia, P. Herrero, J. E. Saffitz, and J. E. Schaffer. 2001. A novel mouse model of lipotoxic cardiomyopathy. J. Clin. Invest. 107: 813-822.
11. Chiu, H. C., A. Kovacs, R. M. Blanton, X. Han, M. Courtois, C. J. Weinheimer, K. A. Yamada, S. Brunet, H. Xu, J. M. Nerbonne, et al. 2005. Transgenic expression of fatty acid transport protein 1 in the heart causes lipotoxic cardiomyopathy. Circ. Res. 96: 225-233.